A perioperative approach with 8-week pre-operative capmatinib followed by 3-year adjuvant capmatinib is being evaluated in the phase II Geometry-N trial, enrolling patients with MET exon 14 mutations and/or high MET amplification stage I-IIIA NSCLC (NCT04926831). The gene discussed is MET; the disease is non-small cell lung carcinoma.